Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide versus liraglutide versus placebo in type 2 diabetes mellitus
2015-005210-30Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide and liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005210-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005210-30.